Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia

Justin Loke; Hrushikesh Vyas; Charles Craddock

doi:10.3389/fonc.2021.666091

Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia

Justin Loke^*, Hrushikesh Vyas, Charles Craddock

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

12 Downloads (Pure)

Abstract

Acute Myeloid Leukemia (AML) is the commonest indication for allogeneic stem cell transplantation (allo-SCT) worldwide. The increasingly important role of allo-SCT in the management of AML has been underpinned by two important advances. Firstly, improvements in disease risk stratification utilizing genetic and Measurable Residual Disease (MRD) technologies permit ever more accurate identification of allo-mandatory patients who are at high risk of relapse if treated by chemotherapy alone. Secondly, increased donor availability coupled with the advent of reduced intensity conditioning (RIC) regimens has substantially expanded transplant access for patients with high risk AML In patients allografted for AML disease relapse continues to represent the commonest cause of transplant failure and the development of novel strategies with the potential to reduce disease recurrence represents a major unmet need.

Original language	English
Article number	666091
Number of pages	15
Journal	Frontiers in Oncology
Volume	11
DOIs	https://doi.org/10.3389/fonc.2021.666091
Publication status	Published - 15 Apr 2021

Bibliographical note

Funding Information:
Conflict of Interest: CC has received honoraria from Celgene, Daichi-Sankyo, Novartis, and Pfizer as well as research funding from Celgene. JL has received travel funding from Novartis and Daichi-Sankyo, and honoraria from Pfizer, Janssen, and Amgen.

Research support and clinical trials funding from CRUK, Bloodwise and Cure Leukaemia acknowledged. Core funding to the Birmingham ECMC Centre program is gratefully acknowledged. The funder bodies were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

Publisher Copyright:
© Copyright © 2021 Loke, Vyas and Craddock.

Keywords

acute myeloid leukemia
allogeneic stem cell transplantation
chemotherapy
graft-vs-host disease
graft-vs-leukemia
MRD (measurable residual disease)

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2021.666091Licence: Creative Commons: Attribution (CC BY)

LokeJ2021OptimizingFinal published version, 1.17 MBLicence: Creative Commons: Attribution (CC BY)

Cite this

@article{4e5c1173c7b141f8af3c82b3aff5dbd3,

title = "Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia",

abstract = "Acute Myeloid Leukemia (AML) is the commonest indication for allogeneic stem cell transplantation (allo-SCT) worldwide. The increasingly important role of allo-SCT in the management of AML has been underpinned by two important advances. Firstly, improvements in disease risk stratification utilizing genetic and Measurable Residual Disease (MRD) technologies permit ever more accurate identification of allo-mandatory patients who are at high risk of relapse if treated by chemotherapy alone. Secondly, increased donor availability coupled with the advent of reduced intensity conditioning (RIC) regimens has substantially expanded transplant access for patients with high risk AML In patients allografted for AML disease relapse continues to represent the commonest cause of transplant failure and the development of novel strategies with the potential to reduce disease recurrence represents a major unmet need.",

keywords = "acute myeloid leukemia, allogeneic stem cell transplantation, chemotherapy, graft-vs-host disease, graft-vs-leukemia, MRD (measurable residual disease)",

author = "Justin Loke and Hrushikesh Vyas and Charles Craddock",

note = "Funding Information: Conflict of Interest: CC has received honoraria from Celgene, Daichi-Sankyo, Novartis, and Pfizer as well as research funding from Celgene. JL has received travel funding from Novartis and Daichi-Sankyo, and honoraria from Pfizer, Janssen, and Amgen. Research support and clinical trials funding from CRUK, Bloodwise and Cure Leukaemia acknowledged. Core funding to the Birmingham ECMC Centre program is gratefully acknowledged. The funder bodies were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Loke, Vyas and Craddock.",

year = "2021",

month = apr,

day = "15",

doi = "10.3389/fonc.2021.666091",

language = "English",

volume = "11",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers",

}

TY - JOUR

T1 - Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia

AU - Loke, Justin

AU - Vyas, Hrushikesh

AU - Craddock, Charles

N1 - Funding Information: Conflict of Interest: CC has received honoraria from Celgene, Daichi-Sankyo, Novartis, and Pfizer as well as research funding from Celgene. JL has received travel funding from Novartis and Daichi-Sankyo, and honoraria from Pfizer, Janssen, and Amgen. Research support and clinical trials funding from CRUK, Bloodwise and Cure Leukaemia acknowledged. Core funding to the Birmingham ECMC Centre program is gratefully acknowledged. The funder bodies were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. Publisher Copyright: © Copyright © 2021 Loke, Vyas and Craddock.

PY - 2021/4/15

Y1 - 2021/4/15

N2 - Acute Myeloid Leukemia (AML) is the commonest indication for allogeneic stem cell transplantation (allo-SCT) worldwide. The increasingly important role of allo-SCT in the management of AML has been underpinned by two important advances. Firstly, improvements in disease risk stratification utilizing genetic and Measurable Residual Disease (MRD) technologies permit ever more accurate identification of allo-mandatory patients who are at high risk of relapse if treated by chemotherapy alone. Secondly, increased donor availability coupled with the advent of reduced intensity conditioning (RIC) regimens has substantially expanded transplant access for patients with high risk AML In patients allografted for AML disease relapse continues to represent the commonest cause of transplant failure and the development of novel strategies with the potential to reduce disease recurrence represents a major unmet need.

AB - Acute Myeloid Leukemia (AML) is the commonest indication for allogeneic stem cell transplantation (allo-SCT) worldwide. The increasingly important role of allo-SCT in the management of AML has been underpinned by two important advances. Firstly, improvements in disease risk stratification utilizing genetic and Measurable Residual Disease (MRD) technologies permit ever more accurate identification of allo-mandatory patients who are at high risk of relapse if treated by chemotherapy alone. Secondly, increased donor availability coupled with the advent of reduced intensity conditioning (RIC) regimens has substantially expanded transplant access for patients with high risk AML In patients allografted for AML disease relapse continues to represent the commonest cause of transplant failure and the development of novel strategies with the potential to reduce disease recurrence represents a major unmet need.

KW - acute myeloid leukemia

KW - allogeneic stem cell transplantation

KW - chemotherapy

KW - graft-vs-host disease

KW - graft-vs-leukemia

KW - MRD (measurable residual disease)

UR - http://www.scopus.com/inward/record.url?scp=85105236352&partnerID=8YFLogxK

U2 - 10.3389/fonc.2021.666091

DO - 10.3389/fonc.2021.666091

M3 - Review article

AN - SCOPUS:85105236352

SN - 2234-943X

VL - 11

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 666091

ER -

Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this